|Home | About | Journals | Submit | Contact Us | Français|
We examined the presence and function of tachykinins and the tachykinin-degrading enzymes neprilysin (NEP) and neprilysin-2 (NEP2) in human spermatozoa.
Freshly ejaculated semen was collected from forty-eight normozoospermic human donors. We analyzed the expression of substance P, neurokinin A, neurokinin B, hemokinin-1, NEP and NEP2 in sperm cells by reverse-transcriptase polymerase chain reaction (RT-PCR), western blot and immunocytochemistry assays and evaluated the effects of the neprilysin and neprilysin-2 inhibitor phosphoramidon on sperm motility in the absence and presence of tachykinin receptor-selective antagonists. Sperm motility was measured using WHO procedures or computer-assisted sperm analysis (CASA).
The mRNAs of the genes that encode substance P/neurokinin A (TAC1), neurokinin B (TAC3), hemokinin-1 (TAC4), neprilysin (MME) and neprilysin-2 (MMEL1) were expressed in human sperm. Immunocytochemistry studies revealed that tachykinin and neprilysin proteins were present in spermatozoa and show specific and differential distributions. Phosphoramidon increased sperm progressive motility and its effects were reduced in the presence of the tachykinin receptor antagonists SR140333 (NK1 receptor-selective) and SR48968 (NK2 receptor-selective) but unmodified in the presence of SR142801 (NK3 receptor-selective).
These data show that tachykinins are present in human spermatozoa and participate in the regulation of sperm motility. Tachykinin activity is regulated, at least in part, by neprilysins.
There is now convincing evidence that tachykinins are involved in the regulation of reproductive function [1-8]. Recent data have demonstrated that tachykinin receptors are present in human sperm and are functionally active suggesting a role for the tachykinin system in the regulation of sperm function .
Mammalian tachykinins comprise a family of regulatory peptides including substance P (SP), neurokinin A (NKA), neurokinin B (NKB) and hemokinin-1 (HK-1) [10-15]. In humans, tachykinins are the products of three different genes. The TAC1 gene gives rise to four different mRNA splicing isoforms (α, β, γ and δ) that encode SP (α, β, γ and δ) and NKA (β and γ). The TAC3 gene encodes NKB. The TAC4 gene can also generate four distinct mRNAs, named α, β, γ and δ, all of which encode HK-1 [1,4,11,12]. Tachykinins effects are mediated by three receptors named NK1, NK2 and NK3, which, in humans, are encoded by the TACR1, TACR2 and TACR3 genes, respectively [15-19]. The NK1 receptor is activated preferentially by SP and HK-1, the NK2 receptor by NKA, and the NK3 receptor by NKB [15-19].
The neutral endopeptidase EC 22.214.171.124, also named enkephalinase or neprilysin (NEP) is the major peptidase that degrades tachykinins in most human tissues [8,20-23]. NEP also degrades other bioactive peptides such as enkephalins, angiotensins, endothelin-1, cholecystokinins and bradykinin [24-28]. The enzyme is expressed in human sperm [9,25-27] and its inhibition by thiorphan causes a change in sperm motility that is partially mediated by opioids . In addition to classical NEP, a homologous enzyme was recently described and named neprilysin-2 (NEP2) . Human NEP2 has much higher substrate specificity and only degrades tachykinins and angiotensin I with efficiency similar to NEP . There are also important differences between enzyme sensitivity to the classical inhibitors, thiorphan and phosphoramidon. Thus thiorphan behaves as a selective NEP inhibitor while phosphoramidon inhibits both enzymes with almost equal potency [24,28]. NEP2 is expressed predominantly in the testis [29-31] and studies in mice deficient in NEP2 have shown that this enzyme is involved in sperm function and oocyte fertilization . However, the role of NEP2 in human reproduction has not jet been established.
In the present study, we investigated the expression and cellular localization of tachykinins and the tachykinin-degrading enzymes NEP and NEP2 in human spermatozoa, analyzed the effects of the NEP and NEP2 inhibitor phosphoramidon on sperm motility, and determined whether endogenous tachykinins are involved in the responses observed after neprilysin inhibition.
SR140333, SR48968 and SR142801 were a generous gift from Sanofi Recherche (Montpellier, France). Phosphoramidon was from Sigma (St. Louis, MO, USA). Drugs were dissolved in distilled water (phosphoramidon) or absolute ethanol (tachykinin receptor antagonists) and diluted into sperm washing medium to appropriate concentrations.
Freshly ejaculated semen was collected from forty-eight healthy donors (18-35 years old) after 3-4 days of sexual abstinence. The study was approved by the Ethics Committee of Consejo Superior de Investigaciones Científicas (CSIC) and all donors gave written informed consent. The samples were allowed to liquefy at 37°C for 30 min and examined for concentration and motility following World Health Organization (WHO) guidelines . Liquefied semen samples were washed with modified human tubal fluid (mHTF, Irvine Scientific, Santa Ana, CA, USA) supplemented with 0.5% bovine serum albumin (BSA) and processed as previously described . Briefly, sperm suspensions were centrifuged through Spermgrad-125 (Vitrolife, Kungsbacka, Sweden), washed in mHTF, allowed to swim-up for 1 hour at 37°C and the supernatant carefully aspirated. Semen motility and concentration were visually re-examined and the concentration adjusted to 50 million per ml for subsequent experiments.
Total RNA was extracted from sperm pools from 8 different donors using TriReagent (Sigma) and cDNA was synthesized using the Quantitect Reverse Transcription kit (Qiagen, Venlo, The Netherlands). Specific oligonucleotide primer pairs used to amplify TAC1, TAC3, TAC4, the α, β, γ and δ isoforms of TAC1 and TAC4, the genes that encode NEP (MME), NEP2 (MMEL1), β-actin (ACTB) acrosin (ACR) and CD4 are shown in Table Table11 and were synthesized and purified by Sigma Genosys (Cambridge, UK). ACTB served as an internal control while ACR and CD4 were used to verify the presence of sperm cDNA and to exclude the presence of leukocyte contamination, respectively [33-35]. Gene expression was also analyzed in human testis and in a pool of cDNAs from twenty different human tissues (human total RNA master panel, BD Biosciences Clontech, Palo Alto, CA) used as a positive control of amplification.
Amplification was performed in PCR buffer containing 3 μl of cDNA reaction mixture, 2.5 mM MgCl2, 0.2 μM primers, 200 μM dNTP's and 1.5 U of DNA polymerase (Immolase, Bioline, London, UK). Cycling parameters were: 15 s at 94°C; 20 s at 60°C and 20 s at 72°C for 35 cycles. In some experiments, a 1/50 dilution of amplified cDNA was reamplified in the same PCR conditions and with the same primers. The PCR products were separated by gel electrophoresis on 2.5% agarose. The amplicon sizes were verified by comparison with a DNA size ladder and the identity of the products was established by sequence analysis.
Sperm cells were washed, resuspended in phosphate-buffered saline (PBS) and smeared onto poly-L-lysine-coated slides. Spermatozoa were fixed in cold methanol (-20°C, 20 min) and incubated with 2% casein in PBS for 120 min to block non-specific sites. Test slides were incubated with a primary polyclonal antibody designed to recognize SP (sc-9758, dilution 1:200), NKB (sc-14109, dilution 1:200), HK-1 (sc-47439, dilution 1:500), NEP (sc-9149, dilution 1:200) from Santa Cruz Biotechnology (Santa Cruz, CA); NKA (T-4446, dilution 1:400), NKB (T-4450, dilution 1:400) from Peninsula Laboratories Inc. (San Carlos, CA) and NEP2 (HPA 007876, dilution 1:400, recommended by the supplier for immunocytochemistry and sc-104450, dilution 1:100, recommended for western blot) from Sigma and Santa Cruz, respectively. Primary antibodies were incubated overnight at 4°C diluted in PBS. The specificity of antibodies was assessed by bibliographic references or by pre-absorption with the corresponding immunogenic peptide. Negative control slides were not exposed to the primary antibody and were incubated with a) rabbit or goat IgG or b) PBS and processed in the same conditions as the test slides. Samples were incubated for 60 min with appropriate FITC-conjugated secondary antibodies (Santa Cruz), mounted using Prolong Gold antifade reagent (Invitrogen, Molecular Probes, Eugene, OR) and examined with an Olympus BX-51 fluorescence microscopy (Tokyo, Japan).
Western blotting was used to assess the specificity of NEP and NEP2 antibodies and performed essentially as described previously . Sperm cells were obtained as indicated above. Seminal plasma was obtained by centrifugation of semen samples at 12000 × g for 10 min. Total proteins from semen or seminal plasma samples were extracted by sonication in urea extraction buffer (1% w/v SDS, 9 M Urea, 1 mM EDTA, 0.7 M mercapto-ethanol, in 25 mM Tris-HCl, pH 6.8), boiled for 2 min and processed by the PAGEprep Advance kit (Pierce, Rockford, IL). Proteins were separated by electrophoresis on 10% SDS-PAGE gels, transferred to polyvinyldifluoride (PVDF) membranes and processed with the Amersham advance ECL kit (Amersham, Buckinghamshire, UK). Primary antibody dilution was 1:10000 and for the secondary antibody was 1:100000.
Motility analysis was performed manually or using a computer-assisted sperm analysis (CASA) system (Sperm Class Analyzer, Microptic, Barcelona, Spain) essentially as described previously [9,33]. Aliquots of semen samples (5 μL) were placed into a Makler Counting Chamber (Sefi Medical Instruments Ltd., Haifa, Israel) and at least 200 sperm cells were evaluated at each incubation time by phase contrast microscopy. Sperm movement was graded following WHO guidelines  and defined as: a: rapid progressive motility; b: slow progressive motility; c: non-progressive motility and d: immotility. Progressive motility (a+b), non-progressive motility (c) and immotility (d) were measured as percentage of the total (a+b+c+d) that was considered as 100%.
Individual sperm samples were divided in several aliquots and each aliquot was untreated (time-matched paired controls) or treated with a single concentration of phosphoramidon (1 nM-1 μM) or the corresponding solvent. Sperm motility was measured 5 min before agent addition (initial value) and after 1, 15, 60, 120 and 240 min contact time periods. The effect of phosphoramidon (1 μM) or its solvent were also investigated in aliquots pretreated for 45 min with the tachykinin NK1 receptor-selective antagonist SR140333 (10 nM) , the NK2 receptor-selective antagonist SR48968 (10 nM) , the NK3 receptor-selective antagonist SR142801 (10 nM) , a cocktail of the three antagonists (10 nM each) or the corresponding solvent. A maximum of two drug concentrations, or the corresponding solvent volume, were tested on each aliquot. Values of sperm progressive motility, non-progressive motility and immotility were expressed as the positive or negative percentage increment in motility produced by the drug relative to the value observed at the same time in solvent-treated or time-matched paired controls (Δ sperm motility).
The effects of phosphoramidon on sperm kinetic parameters were analyzed by CASA, with settings according to instructions by the manufacturer. The measured kinetic parameters were curvilinear velocity (VCL); straight-line velocity (VSL), average path velocity (VAP); percent linearity (LIN = VSL/VCL × 100) and percent straightness (STR = VSL/VAP × 100).
Values (means ± SEM) were obtained by pooling individual data and n indicates the number of experiments in samples from n different donors. Statistical analyses were made using Mann-Whitney's U (for comparison of mean ranks between two groups) or Kruskal-Wallis (to compare more than two groups) nonparametric tests. These procedures were undertaken using GRAPHPAD PRISM (version 5.0). P < 0.05 values were considered significant.
The genes that encode SP/NKA (TAC1), NKB (TAC3), hHK-1(TAC4), NEP (MME) and NEP2 (MMEL1) were detected in cDNAs from human sperm, testis and the pool of 20 human tissues used as positive control (Fig. (Fig.1).1). In sperm, the mRNAs of TAC4 and MME were only visualized after cDNA reamplification. Using specific primers and cDNA reamplification, we observed that, among the TAC1 isoforms, only the γ and δ transcripts were detectable in human spermatozoa (Fig. (Fig.1).1). TAC1-β, TAC1-γ and TAC1-δ were expressed in human testis, the last one being only observed after cDNA reamplification. Splice variants of the TAC4 gene were present in the positive control but were undetected in testis and sperm cDNAs (data not shown). We also verified the presence of ACTB and ACR and the absence of CD4 mRNA in all sperm samples (Fig. (Fig.1,1, not shown for ACTB).
Three negative controls were included in all assays (no reverse transcriptase, no RNA in the reverse transcriptase reaction and no template) and no PCR product was detected in any of these controls.
Immunocytochemistry demonstrated positive immunostaining for tachykinins, NEP and NEP2 in sperm cells (Figs. (Figs.2,2, ,33 and and4).4). Intense SP labeling was observed over the acrosomal region and around the connecting piece in approximately 80% of the cells. In the other cells, SP immunostaining was only observed around the connecting piece and the flagellum principal piece (Fig. (Fig.2A).2A). NKA was mainly found around the neck with a less intense immunostaining of the sperm head and the flagellum principal piece. NKB immunofluorescence was restricted to the equatorial segment and the post-equatorial region of the head (Fig. (Fig.2A).2A). We found identical NKB immunolocalization with two different antibodies. HK-1 was present in the postacrosomal region and along the tail and intense labeling was detected in the flagellum midpiece being the only tachykinin that was present in this sperm area (Fig. (Fig.2B).2B). Preincubation of the primary antiserum with SP or HK-1 immunogenic peptide (5 μg/ml) caused a disappearance of the fluorescent signal (Fig. (Fig.2B,2B, not shown for SP). NEP immunostaining was localized in the equatorial segment in approximately 80% of cells, detected around the neck in a small, different population of sperm cells (approximately 3%) or undetectable (Fig. (Fig.3A).3A). NEP2 was localized around the equatorial segment and the post-acrosomal region of spermatozoa with the HPA 007876 antibody (Fig. (Fig.3A).3A). Unspecific binding was not observed in the presence of preimmune rabbit or goat serum and there was no immunofluorescence in the absence of the corresponding primary antibody.
Western blot confirmed the specificity of NEP and NEP2 antibodies and showed the presence of both enzymes in seminal plasma and of NEP2 in spermatozoa. The NEP antibody labeled a band of approximately 100 kDa (Fig. (Fig.3B).3B). In agreement with previous data  the NEP signal was not observed in sperm. The NEP2 antibody HPA 007876, used in immunocytochemistry studies, recognized a band of approximately 90 kDa, the size expected for the major membrane-bound human NEP2 isoform . As a positive control, we used a second human NEP2 antibody, sc-104450, recommended by the supplier for western blot. This second NEP2 antibody labeled the 90 kDa band in both spermatozoa and seminal plasma (Fig. (Fig.3B).3B). In seminal plasma it recognized a second band, of approximately 130 kDa, which may correspond to an already described, additional membrane-associated isoform or to the soluble form of human NEP2 . A third unknown band of approximately 50 kDa was detected with the sc-104450 antibody in seminal plasma and sperm cells. The immunoreactive bands for NEP and NEP2 were not observed when primary antibodies were omitted (data not shown).
The NEP and NEP2 inhibitor phosphoramidon caused time- and concentration-dependent increases in the proportion of progressively motile sperm (Fig. (Fig.4).4). The magnitude of the effect of phosphoramidon was inversely related to the initial proportion of progressive motile sperm in the sample. Thus, in samples with initial values of sperm progressive motility of 45-60%, the percentage of grade a+b sperm was 64.8 ± 3.8 in samples treated with 1 μM phosphoramidon for 60 min and 51.0 ± 3.2 in time-matched paired aliquots (P < 0.05). Sperm progressive motility was not affected by the phosphoramidon solvent (50.0 ± 3.3, P > 0.05 vs. time-matched controls). The results were similar when sperm motility was measured manually (Fig. 4A, B) or by CASA (Fig. (Fig.4C).4C). The use of CASA revealed that phosphoramidon increased particularly the percentage of grade a spermatozoa (Fig. (Fig.4C).4C). With regard to sperm kinetimatic parameters, CASA analysis showed that phosphoramidon increased straightness (by 6.13 ± 1.74%) and linearity (by 7.56 ± 0.98%) (P < 0.05 vs. solvent-treated aliquots) leading to a motility pattern characteristic of non-hyperactivated sperm.
We then analyzed whether tachykinin receptors could mediate the actions of phosphoramidon on sperm motility. The effect of phosphoramidon (1 μM, 60 min incubation) was reduced by preincubation of the sperm sample for 45 min with the NK1 receptor-selective antagonist SR140333 (10 nM) or the NK2 receptor-selective antagonist SR48968 (10 nM) but was not affected by the NK3 receptor-selective antagonist SR142801 (10 nM) (Fig. (Fig.5).5). The phosphoramidon-induced effect was reduced, but not abolished, in the presence of a combination of the three tachykinin receptor antagonists (each at a concentration of 10 nM, Fig Fig5).5). The antagonist solvent had no effect on phosphoramidon responses (Fig (Fig55).
In the present study, the major findings are: a) the tachykinin peptides, SP, NKA, NKB and HK-1 are present in human sperm; b) the two most important enzymes involved in tachykinin metabolism, NEP and NEP2 are expressed in human spermatozoa and c) the endogenous tachykinins modulate the motility of these cells.
The mRNAs of TAC1, TAC3 and TAC4, coding for the human tachykinin peptides, were expressed in sperm (9, this study). Among the TAC1 isoforms, only TAC1-γ and the rare TAC1-δ were present in spermatozoa. Conversely, the α and β isoforms were absent, in spite of the fact that TAC1-β is one of the most abundant TAC1 isoforms in many human cells and tissues including the testis [2,6,14]. With respect to TAC4, none of its splicing variants was detected. Increasing evidence suggests that the specific fraction of mRNAs that stays in mature spermatozoa plays some role in subsequent fertilization steps or is required for adequate embryo formation [39-42]. In this context, recent reports have established the existence of important differences between the sperm transcriptome of fertile and infertile men  providing clinical support for the relevance of sperm mRNA in male fertility.
The mRNAs of all tachykinins were present in human testis and sperm. Because spermatozoa are considered transcriptionally silent cells, the presence of these mRNA unequivocally proves that the genes encoding these proteins are transcribed in germ cells at any step during spermatogenesis. In addition, immunocytochemistry studies revealed that all tachykinin peptides were present in mature spermatozoa. Major labeling was observed over the acrosomal region for SP, around the connecting piece for NKA, in the equatorial/post-acrosomal region for NKB and around the midpiece for HK-1. This regional pattern of distribution argues for a specific role for each tachykinin in the regulation of sperm function. The presence of NKB in the equatorial segment suggests that this tachykinin could be involved in the fertilization process because this segment appears important in the fusion of gametes . It has recently been shown that the NKB/NK3 ligand-receptor pair plays a central role in the regulation of reproductive functions [4-9]. In this context, it is interesting to note that NKB immunostaining was in a similar location than that previously found for the tachykinin NK3 receptor .
The local bioactivity of peptide signaling molecules is tightly controlled by their enzymatic degradation. Our data show that NEP and NEP2, the most important enzymes involved in tachykinin metabolism, are expressed in human sperm at both mRNA and protein levels. In reference to NEP, the data confirm previous results showing the expression of this enzyme in sperm [25-27]. With respect to NEP2, we report for the first time the presence of this enzyme in human spermatozoa. The observation that NEP2 was placed around the equatorial segment of human spermatozoa support a role for this enzyme in sperm fertilizing ability. These data are in line with previous findings showing that sperm from NEP2 knockout mice show apparently normal characteristics but lower oocyte fertilization and reduced embryo development .
NEP and NEP2 were abundant in seminal plasma suggesting that the activity of their substrates must be strictly controlled during the last maturation steps in the male reproductive tract and/or during ejaculation. In mature spermatozoa, inhibition of both enzymes by phosphoramidon caused an increase in sperm progressive motility. Sperm motility is an important feature and the most reliable actual predictor of male factor infertility [44,45]. Our data show that phosphoramidon induced a rise in straightness and linearity leading to motility trajectories that are characteristics of non hyperactivated spermatozoa and this is important because only spermatozoa with good progressive motility are able to swim through the female reproductive tract and reach the oviduct.
The responses elicited by phosphoramidon were reduced in the presence of SR140333, a selective antagonist of the tachykinin NK1 receptor , and in the presence of SR48968, a selective antagonist of the tachykinin NK2 receptor . This demonstrates that the effects observed after neprilysin inhibition are mediated, at least in part, by tachykinins acting at the NK1 and the NK2 receptor. Conversely, the effects of phosphoramidon were unaffected in the presence of SR142801, a selective antagonist of the tachykinin NK3 receptor , consistent with our previous data which showed that the NK3 receptor plays a minor role in mediating motility changes induced by exogenously applied tachykinins in human sperm .
The effects of phosphoramidon were reduced, but not abolished, in the presence of a combination of SR140333, SR48968 and SR142801. NEP and NEP2 participate in degradation of other peptides, such as angiotensin-1, bradykinin and enkephalins which are also implicated in sperm cell function [27,28] and might thus be relevant to explain the tachykinin antagonist-resistant component of the response to phosphoramidon. In fact, the NEP inhibitor thiorphan increased sperm progressive motility and the opioid receptor antagonist naloxone inhibited the effects observed after prolonged (4 h) but not shorter (2 h) periods of incubation with thiorphan . It thus seems that both tachykinins and opioids are involved in the responses observed after neprilysin inhibition in human sperm without ruling out the possible involvement of other peptide substrates.
Bioactive peptides i.e., opioids , bradykinin  or tachykinins [, this study] are widely expressed in sperm and many of the enzymes involved in their metabolism are also present and are functionally active [25,27,28]. Inhibition of these enzymes caused slowly developing changes in sperm motility [[27,28], this study]. Thus, these biopeptides, and particularly tachykinins, could operate as signal molecules between spermatozoa and their environment acting in an autocrine and/or paracrine (effect on other cells, on the female genital tract, and viceversa) fashion. In fact, NK1 NK2 and NK3 receptors are present in sperm and exogenously applied tachykinins modulate progressive motility at nanomolar concentrations . Further studies will help to clarify the precise role of neprilysins and neprylisin-sensitive peptides in the regulation of sperm physiology and male fertility.
The present study shows that tachykinins and the tachykinin-degrading enzymes NEP and NEP2 are present in human spermatozoa and participate in the regulation of sperm motility. These data support a role for the tachykinin system in the regulation of sperm function.
SP: substance P; NKA: neurokinin A; NKB: neurokinin B; HK-1: hemokinin-1; NEP: neprilysin; NEP2: neprilysin-2; BSA: bovine serum albumin; RT-PCR: reverse-transcriptase polymerase chain reaction; CASA: computer-assisted sperm analysis; WHO: World Health Organization; MHTF: modified human tubal fluid; PBS: phosphate-buffered saline.
The authors declare that they have no competing interests.
FMP carried out RT-PCR, western blot analysis and participated in the design of the study. NS and ACR carried out motility studies and immunofluorescence experiments. CGR and MFS participated in sample collection and analysis of sperm parameters. NG, JI and LC wrote the manuscript and participated in the design of the study. All authors read and approved the final manuscript.
This work was supported by grants from Junta de Andalucía (P08-CVI-04185) and Ministerio de Educación y Ciencia (CTQ2007-61024/BQU), Spain. A. Cejudo-Román is supported by Junta de Andalucia, Spain.